相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prevalence of statin intolerance: a meta-analysis
Ibadete Bytyci et al.
EUROPEAN HEART JOURNAL (2022)
Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)
Peter E. Penson et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2022)
Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials
Emily Herrett et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Intensity of statin therapy and muscle symptoms: a network meta-analysis of 153 000 patients
John W. Davis et al.
BMJ OPEN (2021)
Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019 Update From the GBD 2019 Study
Gregory A. Roth et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects
Frances A. Wood et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials
Jordan Fulcher et al.
LANCET (2019)
Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease Data From UK Biobank
Claire Welsh et al.
CIRCULATION (2019)
Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association
Connie B. Newman et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
Scott M. Grundy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase
Ajay Gupta et al.
LANCET (2017)
Protocol for analyses of adverse event data from randomized controlled trials of statin therapy
C. Reith et al.
AMERICAN HEART JOURNAL (2016)
Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance The GAUSS-3 Randomized Clinical Trial
Steven E. Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
The nocebo effect in the context of statin intolerance
Jonathan A. Tobert et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2016)
Interpretation of the evidence for the efficacy and safety of statin therapy
Rory Collins et al.
LANCET (2016)
Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial
Patrick M. Moriarty et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2015)
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials
Jordan Fulcher et al.
LANCET (2015)
A systematic review of statin-induced muscle problems in clinical trials
Harsha V. Ganga et al.
AMERICAN HEART JOURNAL (2014)
Should people at low risk of cardiovascular disease take a statin?
John D. Abramson et al.
BMJ-BRITISH MEDICAL JOURNAL (2013)
Statin Use and Musculoskeletal Pain Among Adults With and Without Arthritis
Catherine Buettner et al.
AMERICAN JOURNAL OF MEDICINE (2012)
Everyone under statin?
Helene Vaillant-Roussel et al.
EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE (2012)
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
B. Mihaylova et al.
LANCET (2012)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
C. Baigent et al.
LANCET (2010)
Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial
Jane Armitage et al.
LANCET (2010)
Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Bengt C. Fellstroem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial
Luigi Tavazzi et al.
LANCET (2008)
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Rosuvastatin in older patients with systolic heart failure
John Kjekshus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Efficacy and safe of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes - The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN)
Robert H. Knopp et al.
DIABETES CARE (2006)
Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients -: The PRIMO study
E Bruckert et al.
CARDIOVASCULAR DRUGS AND THERAPY (2005)
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
C Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Intensive lipid lowering with atorvastatin in patients with stable coronary disease
JC LaRosa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Intensive versus moderate lipid lowering with statins after acute coronary syndromes
CP Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes - Phase Z of the A to Z trial
JA de Lemos et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
HM Colhoun et al.
LANCET (2004)
Effect of fluvastatin on cardiac outcomes in renal transplant recipients:: a multicentre, randomised, placebo-controlled trial
H Holdaas et al.
LANCET (2003)
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA):: a multicentre randomised controlled trial
PS Sever et al.
LANCET (2003)
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
J Shepherd et al.
LANCET (2002)
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial
R Collins et al.
LANCET (2002)
Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention - A randomized controlled trial
PWJC Serruys et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials
R Collins et al.
LANCET (2001)
分享论文
